Illinois HB4834 amends the Illinois Controlled Substances Act to exclude testosterone, mifepristone, misoprostol, GnRH analogues, and estrogen from.
HB4834 amends the Illinois Controlled Substances Act by modifying the Prescription Monitoring Program to exclude testosterone, mifepristone, misoprostol, GnRH analogues, and estrogen from its scope. The Department of Human Services is required to purge existing records related to these substances by January 1, 2027. The bill also mandates that healthcare facilities and their Electronic Health Records Systems or Pharmacy Management Systems interface with the Prescription Monitoring Program by January 1, 2024.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.